retatrutide sleepy VisualAbstract: reduces body weight by 17.5% in patients with obesity What to Know About Retatrutide

Noom's approach acknowledges that medication alone addresses appetite but not eating patterns or psychological drivers

Glucagon-like peptide-1 receptor agonist use corresponded with risk reductions for dozens of diseases and adverse health outcomes, such as dementia and stroke, a new analysis published in Nature Medicine showed

Stability Data Summary (available upon request)

Tesamorelin, known for stimulating growth hormone release, and retatrutide, which has demonstrated up to a 24.2% weight reduction over 48 weeks, both show impressive individual results

Discontinuations of one or two years without resuming GLP-1 use resulted in a 14% or 22% increased risk of cardiovascular events, respectively, compared to staying on the drugs